Dr. Ramona Doyle, M.D., has been Chief Medical Officer of Blade Therapeutics, Inc. since June 20, 2017. Dr. Doyle leads clinical development strategy and execution. She has extensive experience in clinical trial design and execution, as well as regulatory and commercial strategy. She served as Vice President of Therapeutics at the California Institute of Regenerative Medicine (CIRM), where she helped design and launch a strategic overhaul of this California state agency tasked with disbursing $3 billion research dollars. Previously, she served as Senior Group Medical Director for Respiratory Product Development at Genentech, leading an international team of scientists and clinicians developing programs in five different disease areas. In 2014, Dr. Doyle was the Roche R&D lead for the acquisition of InterMune, Inc., and its drug Esbriet® (pirfenidone) for idiopathic pulmonary fibrosis (IPF). Prior to her tenure at Genentech, she served as Director of Medical Affairs at Gilead, where she led the respiratory and cardiovascular disease franchise. Dr. Doyle is also a clinical professor of medicine at UCSF. She was on the faculty at Stanford University School of Medicine for 12 years, during which time she served as the Medical Director of the Lung and Heart-Lung Transplantation Program and founded a program in pulmonary hypertension. She completed her training in internal medicine, as well as a fellowship in pulmonary and critical care medicine, at the University of California at San Francisco (UCSF) Medical Center. Dr. Doyle is Board-certified in Pulmonary and Critical Care. She received her BA degree from the University of the South (Sewanee), BA and M.Sc. degrees from Oxford University in England and her MD degree from Emory University in Atlanta. Dr. Ramona Doyle, M.D., has been Chief Medical Officer of Blade Therapeutics, Inc. since June 20, 2017. Dr. Doyle leads clinical development strategy and execution. She has extensive experience in clinical trial design and execution, as well as regulatory and commercial strategy. She served as Vice President of Therapeutics at the California Institute of Regenerative Medicine (CIRM), where she helped design and launch a strategic overhaul of this California state agency tasked with disbursing $3 billion research dollars. Previously, she served as Senior Group Medical Director for Respiratory Product Development at Genentech, leading an international team of scientists and clinicians developing programs in five different disease areas. In 2014, Dr. Doyle was the Roche R&D lead for the acquisition of InterMune, Inc., and its drug Esbriet® (pirfenidone) for idiopathic pulmonary fibrosis (IPF). Prior to her tenure at Genentech, she served as Director of Medical Affairs at Gilead, where she led the respiratory and cardiovascular disease franchise. Dr. Doyle is also a clinical professor of medicine at UCSF. She was on the faculty at Stanford University School of Medicine for 12 years, during which time she served as the Medical Director of the Lung and Heart-Lung Transplantation Program and founded a program in pulmonary hypertension. She completed her training in internal medicine, as well as a fellowship in pulmonary and critical care medicine, at the University of California at San Francisco (UCSF) Medical Center. Dr. Doyle is Board-certified in Pulmonary and Critical Care. She received her BA degree from the University of the South (Sewanee), BA and M.Sc. degrees from Oxford University in England and her MD degree from Emory University in Atlanta.

Cellular & Molecular Pathology